Company / Operating Cash Flow per Share
Celldex Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.17
FY2025
5-year range
-$3.17 / -$1.30
FY2021-FY2025
Trend
-33.3%
vs FY2024
Sector context
#156 of 162
Health Care
What the data says
Among 162 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 4% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-12.24 in FY2018 to $-0.83 in FY2017.
Based on SEC 10-K filings.
-3.17 in FY2025.
Declined from $-1.92 to $-3.17 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 162This company -$3.17 Sector average $6.63
▼
-147.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 33.3% year-over-year.
- Ranks #156 out of 162 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2017.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.17 | -33.3% |
| FY2024 | -$2.38 | -23.8% |
| FY2023 | -$1.92 | +12.6% |
| FY2022 | -$2.20 | -68.6% |
| FY2021 | -$1.30 | -27.8% |
| FY2020 | -$1.02 | +62.7% |
| FY2019 | -$2.73 | +77.7% |
| FY2018 | -$12.24 | -1376.2% |
| FY2017 | -$0.83 | +11.6% |
| FY2016 | -$0.94 | +6.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026